Thromboembolism Therapy
Dalteparin based on body weight safe for thromboembolism in obesity
Published in Obesity and Diabetes Week, March 21st, 2005
"Data evaluating the safety of using weight-based low-molecular-weight heparin in the treatment of obese patients with acute venous thromboembolism are limited. The product monograph of dalteparin suggests the maximum dose should be limited to 18,000 U subcutaneously once daily. There are no specific data regarding the risk of recurrence or bleeding in patients given dalteparin in a weight-based dose of 200 IU/kg," scientists in Canada report.
"We report a retrospective chart review of 193 obese patients who weighed more than 90...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diet and Nutrition
Diets decrease C-reactive protein by affecting adipocyte function - Diet and Nutrition
Low-AGE content of low-fat vegan diets could benefit diabetic patients - Obesity and Diabetes
Diet-induced obesity upregulates glucocorticoid metabolism - Obesity and Diabetes
Protein secreted by visceral fat mimics effects of insulin - Obesity and Diabetes
Reduced insulin reserve plays major role in progression of diabetes - Addison Disease
Diabetes plus 21-hydroxylase antibodies raises Addison disease risk - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
